Dowling & Yahnke’s Actinium Pharmaceuticals ATNM Stock Holding History

Dowling & Yahnke’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-762	Closed	-$8K	–	308
2020 Q2	$8K	Hold	762	–	–	﹤0.01%	299
2020 Q1	$4K	Hold	762	–	–	﹤0.01%	291
2019 Q4	$5K	Hold	762	–	–	﹤0.01%	354
2019 Q3	$5K	Hold	762	–	–	﹤0.01%	305
2019 Q2	$6K	Hold	762	–	–	﹤0.01%	294
2019 Q1	$11K	Hold	762	–	–	﹤0.01%	256
2018 Q4	$13K	Hold	762	–	–	﹤0.01%	248
2018 Q3	$17K	Hold	762	–	–	﹤0.01%	281
2018 Q2	$15K	Hold	762	–	–	﹤0.01%	274
2018 Q1	$8K	Hold	762	–	–	﹤0.01%	281
2017 Q4	$15K	Hold	762	–	–	﹤0.01%	290
2017 Q3	$13K	Hold	762	–	–	﹤0.01%	278
2017 Q2	$28K	Hold	762	–	–	﹤0.01%	274
2017 Q1	$35K	Hold	762	–	–	﹤0.01%	274
2016 Q4	$20K	Hold	762	–	–	﹤0.01%	263
2016 Q3	$31K	Hold	762	–	–	﹤0.01%	262
2016 Q2	$40K	Hold	762	–	–	﹤0.01%	264
2016 Q1	$46K	Hold	762	–	–	0.01%	256
2015 Q4	$74K	Buy	+762	New	+$50.6K	0.01%	249

Other funds holding ATNM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dowling & Yahnke's ATNM Position: Q3 2020 in Review

Dowling & Yahnke sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 762 shares — an estimated $8K sold.

Dowling & Yahnke first reported a position in ATNM in Q4 2015 and held it in 19 quarters. The position peaked at $74K in Q4 2015. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

Dowling & Yahnke reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Dowling & Yahnke sold 762 Actinium Pharmaceuticals shares in Q3 2020, an estimated $8K.
Dowling & Yahnke first reported a position in Actinium Pharmaceuticals in Q4 2015 and held it in 19 quarters.
Dowling & Yahnke's Actinium Pharmaceuticals position peaked at $74K in Q4 2015.
41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Dowling & Yahnke's 13F filing for Q3 2020, filed 19 Oct 2020.